Research programme: paclitaxel inhalation - Ventaira

Drug Profile

Research programme: paclitaxel inhalation - Ventaira

Latest Information Update: 15 Jan 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ventaira Pharmaceuticals
  • Developer National Cancer Institute (USA); Ventaira Pharmaceuticals
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lung cancer

Most Recent Events

  • 29 Oct 2007 Ventaira Pharmaceuticals has been acquired and merged into Battelle
  • 08 Jan 2004 BattellePharma is now called Ventaira Pharmaceuticals
  • 24 May 2002 Battelle Pulmonary Therapeutics is now called BattellePharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top